Suvorexant and Alcohol
- Conditions
- Alcohol Use Disorder
- Interventions
- Registration Number
- NCT06326684
- Lead Sponsor
- University of Kentucky
- Brief Summary
This research will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for alcohol, as well as other alcohol-associated maladaptive behaviors in people with Alcohol Use Disorder. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of alcohol in humans. As such, the outcomes will contribute to our understanding of the clinical neurobiology of Alcohol Use Disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on alcohol addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
Not provided
- Able to speak and read English.
- Not seeking treatment at the time of the study.
- Between the ages of 21 and 55 years.
- Engaging in at least one binge drinking episode, per the NIAAA definition, in the last 30 days.
- Fulfillment of moderate or severe DSM-5 diagnostic criteria for AUD based on computerized SCID results reviewed by a psychiatrist or psychologist.
- ECG, read by cardiologist, within normal limits.
- Body mass index of 19 - 35.
- Birthing individuals using an effective form of birth control and not pregnant or breast feeding.
- Judged by the medical staff to be psychiatrically and physically healthy (i.e., no current severe SUD or psychiatric diagnoses other than AUD or Tobacco Use DisorderĶ¾ no current physical diagnoses that would interfere with study participation according to study physician judgment).
- Not currently physiologically dependent on any substances.
- Able to abstain from alcohol during admission (i.e., not physically dependent on alcohol and scores less than 8 on Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar] at screening).
- Not currently taking any prescribed medications for a chronic condition (other than birth control).
- No indication of sleep apnea on the STOP-Bang questionnaire (score of 5 or greater).
- No contraindications/allergies to suvorexant.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Suvorexant Dose 1 Suvorexant Subjects will be treated daily with oral suvorexant (10 mg). Suvorexant Dose 2 Alcohol Subjects will be treated daily with oral suvorexant (20 mg). Placebo Placebo Subjects will be treated daily with an oral placebo. Placebo Alcohol Subjects will be treated daily with an oral placebo. Suvorexant Dose 1 Alcohol Subjects will be treated daily with oral suvorexant (10 mg). Suvorexant Dose 2 Suvorexant Subjects will be treated daily with oral suvorexant (20 mg).
- Primary Outcome Measures
Name Time Method Reinforcing Effects of Alcohol 6 times over approximately 2.5 week inpatient admission. Number of Times Subjects Choose Alcohol (Maximum of 5 Choices) Over Money
- Secondary Outcome Measures
Name Time Method Breath Alcohol Level Daily over approximately 2.5 week inpatient admission. Percent. Measured daily during inpatient admission.
Side Effects Daily over approximately 2.5 week inpatient admission. Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.
Delay Discounting 6 times over approximately 2.5 week inpatient admission. Subjects will complete the delay discounting task during 6 sessions while they are admitted to our inpatient unit. Responses will be used to calculate discounting slope (i.e., K).
Alcohol Response 6 times over approximately 2.5 week inpatient admission. Subjects will complete the Biphasic Alcohol Effects Scale during 6 sessions while they are admitted to our inpatient unit. Scores range from 0 to 10 with higher scores indicating greater responses.
Blood pressure Daily over approximately 2.5 week inpatient admission. mm Hg. Measured daily during inpatient admission.
n-back Task 6 times over approximately 2.5 week inpatient admission. Subjects will complete the n-back task during 6 sessions while they are admitted to our inpatient unit. Percentage of correct responses will be the outcome.
Heart rate Daily over approximately 2.5 week inpatient admission. Beats per minute. Measured daily during inpatient admission.
Stop-Signal Task Inhibitory Failures 6 times over approximately 2.5 week inpatient admission. Subjects will complete the stop-signal task during 6 sessions while they are admitted to our inpatient unit. Proportion of inhibitory failures will be the outcome variable.
Craving 6 times over approximately 2.5 week inpatient admission. Subjects will report their craving during 6 sessions while they are admitted to our inpatient unit. Measured using a 10 point craving questionnaire with higher scores meaning greater craving.
Mood 6 times over approximately 2.5 week inpatient admission. Subjects will complete the Profile of Mood States during 6 sessions while they are admitted to our inpatient unit. Scores range from 0 to 4 with higher scores indicating stronger mood.
Temperature Daily over approximately 2.5 week inpatient admission. Degrees Fahrenheit. Measured daily during inpatient admission.
Sleep Daily over approximately 2.5 week inpatient admission. Subjects will complete the St. Mary's Sleep Questionnaire daily while they are admitted to our inpatient unit. Total sleep time will be the outcome variable and will be recorded in minutes. Higher scores indicate more sleep. Total sleep time is measured by self-report; minimum score=0, maximum score=1440 per day.
Trial Locations
- Locations (1)
Psychopharmacology of Addiction Laboratory
šŗšøLexington, Kentucky, United States